Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) traded up 5% on Monday . The company traded as high as $133.97 and last traded at $132.98. 178,594 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 863,770 shares. The stock had previously closed at $126.70.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on NBIX shares. StockNews.com lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 1st. BMO Capital Markets lowered their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating for the company in a research note on Thursday, October 17th. Piper Sandler raised shares of Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Royal Bank of Canada reduced their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a report on Friday, October 4th. Finally, Jefferies Financial Group raised their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a "buy" rating in a research report on Monday, August 19th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $165.00.
Get Our Latest Stock Report on NBIX
Neurocrine Biosciences Price Performance
The company has a market capitalization of $13.47 billion, a price-to-earnings ratio of 35.79 and a beta of 0.34. The firm's fifty day moving average price is $121.75 and its 200-day moving average price is $130.59.
Insider Buying and Selling at Neurocrine Biosciences
In other news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares of the company's stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.30% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Neurocrine Biosciences by 0.8% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company's stock valued at $1,574,000 after purchasing an additional 90 shares during the last quarter. Fifth Third Bancorp grew its stake in Neurocrine Biosciences by 14.7% in the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company's stock valued at $99,000 after purchasing an additional 92 shares during the period. Total Clarity Wealth Management Inc. increased its position in shares of Neurocrine Biosciences by 4.3% during the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company's stock valued at $335,000 after purchasing an additional 100 shares during the last quarter. Commerce Bank boosted its stake in Neurocrine Biosciences by 2.6% in the third quarter. Commerce Bank now owns 4,199 shares of the company's stock valued at $484,000 after acquiring an additional 108 shares during the last quarter. Finally, Caprock Group LLC raised its holdings in shares of Neurocrine Biosciences by 7.0% in the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company's stock worth $230,000 after purchasing an additional 109 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.
About Neurocrine Biosciences
(
Get Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Read More
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
